Addressing the Research and Development Gaps in Modern Phage Therapy
Paul E. Turner, Joana Azeredo, Ed T. Buurman, Sabrina I. Green, Jakob Haaber, Douglas Haggstrom, Koïchi Kameda, Claas Kirchhelle, Mercedes González Moreno, Jean‐Paul Pirnay, Mirza Alas Portillo
Abstract
Antimicrobial resistance is on the rise globally, prompting increased research and development (R&D) of phage therapy as a strategy to address difficult-to-treat bacterial infections. We review the current state of phage therapy research, including major operational, epistemic, and biological challenges for phage R&D, and discuss some new approaches to developing the technology motivated by recent breakthroughs such as artificial intelligence and synthetic phage production. In addition, we contextualize these R&D challenges and opportunities in light of the ongoing predicament of commercial antimicrobial innovation and current public-private efforts to reinvigorate the pipeline of antimicrobial drug discovery. We conclude with reflections on the potential for new phage therapies to be readily accessible across all income contexts to better ensure broad patient access, and consider possible alternatives to current public and public-private solutions for phage therapy and production.